TPWA
TRVI icon

Twin Peaks Wealth Advisors’s Trevi Therapeutics TRVI Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29
Closed -$346 – 2043
2026
Q1 		$346 Buy
+29
New +$325 ﹤0.01% 2085
2025
Q3 		– Sell
-2
Closed -$15 – 1973
2025
Q2 		$15 Buy
+2
New +$12 ﹤0.01% 2260

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Twin Peaks Wealth Advisors's TRVI Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Trevi Therapeutics (TRVI) in Q2 2026, closing a stake of 29 shares — an estimated $346 sold.

Twin Peaks Wealth Advisors first reported a position in TRVI in Q2 2025 and held it in 2 quarters. The position peaked at $346 in Q1 2026. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Trevi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 29 Trevi Therapeutics shares in Q2 2026, an estimated $346.
  • Twin Peaks Wealth Advisors first reported a position in Trevi Therapeutics in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's Trevi Therapeutics position peaked at $346 in Q1 2026.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.